Suzhou, March 24, 2024 — China Suzhou Innovation Medicine Conference, the 2024 CMAC Annual Meeting, concluded successfully at the Suzhou International Expo Center.
The BD forum is delving into international transactions and development of innovative medicines, moderated by Zhang Ying, Vice President of Clinical Medicine at an innovative pharmaceutical company, led an engaging discussion on the theme "Identifying Drugs with Insight: Standardizing Good Products."
The forum organizer invited top professionals in the industry, including Tong Peirong, Vice President of Business Development at Nian Yan Pharmaceutical, Xie Chao, Senior Director of Oncology Product Line and Project Management at Pfizer, Zhu Bo, Vice President of Clinical Research Medical Research Department at Jin Sai Pharmaceutical, Xiao Liang, Co-founder of Yi Lian Biotech, Huang Ying, General Manager of Product Strategic Development Center at Beijing Kangchen Pharmaceutical, and Mr. Ken Chen, Vice President of Clinical Service Center. These industry leaders shared their insights and experiences in the field of BD transactions over the past few years.
Mr. Ken Chen, Vice President of Clinical Service Center, particularly emphasized that identifying the "Achilles' heel" of each project is key to success in pharmaceutical asset transactions. He introduced how to help clients reassess the value of their assets at different stages of transactions and actively facilitate deals. Mr. Ken Chen also introduce a successful case that Biolink Capital, a platform under Clinical Service Center, assisted a company in formulating an introduction strategy for a Japanese cardiovascular generic drug in the fiercely competitive domestic market.
Mr. Ken Chen, Vice President of Clinical Service Center
Biolink Capital has gained attention for its professional project transaction platform, establishing a comprehensive business system including medical and pharmaceutical asset authorization transactions, investment and financing consulting, and mergers and acquisitions consulting. In addition, Biolink Capital's BD strategy consulting, international market sales channel construction, hospital KOL cultivation, and marketing promotion provide clients with comprehensive commercialization solutions. The company's strong international cooperation network and professional clinical and commercial consulting services, including customized BD strategies, data auditing, asset registration consulting, and clinical development planning, ensure its differentiation competitive advantage in the global pharmaceutical industry.
This BD forum not only provided attendees with a platform to deepen their understanding of industry trends and asset management but also emphasized the determination of industry leaders to facilitate transactions in the face of challenges. As the pharmaceutical industry continues to develop rapidly, such exchanges will undoubtedly promote more cooperation and innovation.